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Background: The germinal center (GC) resident T follicular
helper cells (Tfh) represent a significant fraction of total pool of
HIV/SIV infected cells during chronic infection and HAART.
The GC are generally thought to exclude CD8 T cells and anti-
viral CD8 T cells with potential to migrate to GC (follicular
CD8) may enhance HIV/SIV control and reduce viral reservoirs.
Here we studied the follicular CD8 in a cohort of DNA/MVA
vaccinated rhesus macaques (RM) that controlled or did not
control a pathogenic SIV infection.
Methods: RM were vaccinated with a DNA/MVA SIV vaccine
and challenged intrarectally with SIVmac251. Animals with
viral load below 1,000 copies at set point were defined as con-
trollers. All controller RM (n = 19) were vaccinated and non-
controller RM (n = 18) consisted of both vaccinated and un-
vaccinated.
Results: Post challenge, we observed an aberrant enrichment of
SIV+ PD-1hi CD4 T cells in the LN and rectum of non-con-
trollers but not controllers. The enhanced viral control was as-
sociated with higher frequency of Gag CM9 Tet+ CD8 T cells
in the LN of controller RM compared to non-controller RM. This
was not evident in blood. Interestingly, a significant fraction of
anti-viral CD8 T cells in the controller RM co-expressed
CXCR5 (required for homing to B cell follicles/GC). The fre-
quency of Tet + CXCR5 + granzyme B+ cells was also higher
in the LN of controller RM and higher frequencies correlated
with lower Tfh and enhanced viral control. Immunofluorescence
staining revealed co-localization of CD8 T cells with PD-1bright
cells in IgD- GC, a phenomena not observed in the non-con-
troller RM. Impressively, the CXCR5 + CD8 T cells from the
controller RM restricted the anti-CD3 driven expansion of
CM9 peptide pulsed Tfh cells in vitro suggesting their killing
potential.
Conclusions: Our results reveal a novel subset of anti-viral CD8
T cells that may contribute to enhanced control of pathogenic
SIV infection by infiltrating to GC of lymphoid sites and limiting
SIV replication in Tfh in a vaccine setting.
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Background: A top-down strategy was used to search for ben-
eficial viral targets in large human immunogenicity data and to
identify potential decoy targets that should be avoided in future
vaccine designs.
Methods: Through the identification of beneficial T cell re-
sponses in more than 1000 individuals, the HIVACAT T-cell
immunogen (HTI) was designed to contain 16 HIV-1 protein
segments of 10-70 amino acids in length, covering> 50 optimal
defined CD4 + and CD8 + T-cell epitopes with > 40 different
HLA restrictions, without overrepresentation of B27/B57/B58
restricted epitopes. Heterologous prime-boost regimens com-
bining DNA (D) and MVA (M) expressing HTI were assessed in
C57BL/6 mice and four Indian rhesus macaques. Cellular re-
sponses were characterized using IFN-c ELISPOT and intra-
cellular cytokine assays.
Results: In C57BL/6 mice, DNA.HTI induced broad CD4+ and
CD8 + T-cell responses to all segments within Gag, Pol, Vif and
Nef. These responses were strongly increased by using heter-
ologous regimens consisting of 3x DNA.HTI prime followed by
MVA.HTI boost compared to 3 or 4x DNA.HTI only (median
magnitude DDDM of 3,051 vs 1,401 and 1,353 SFC/106 sple-
nocytes in DDD and DDDD groups respectively, p = 0.0087). In
rhesus macaques, DDD (administered IM in combination with
macaque IL-12 DNA as molecular adjuvant using in vivo elec-
troporation) induced 0.4-1.5 % of specific T cells that persisted
over a period of 4.5 months. MVA.HTI boosted the responses by
3- to 20-fold, reaching 0.4-3.2 % IFN-c T-cells. DDDM induced
central and effector memory responses with a significant fraction
of the vaccine induced IFN-c +CD8 + T cell being either
CD107a + or GzmB + .
Conclusions: HTI delivered in a DDDM regimen was highly
immunogenic in mice and macaques. The responses were CD8 +
and CD4+ effector T cells with cytotoxic potential as well as
CD4 + central memory T cells indicating long-term immuno-
logical persistence. These data justify further testing of the HTI
approach in human clinical trials.
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Background: Monoclonal Ab’s have demonstrated therapeutic
utility against several malignancies and infectious diseases. A
drawback of this strategy is the time-consuming and expensive
process requiring purification and scale up production of the
Ab’s for clinical use. A method to produce antibodies in vivo
would be significant improvement for this platform. It would be
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